Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. OBI Pharma's Free Cash Flow for the
three
months ended in Dec. 2025 was NT$-488.36 Mil. OBI Pharma's Revenue for the
three
months ended in Dec. 2025 was NT$20.84 Mil. Therefore, OBI Pharma's FCF Margin % for the quarter that ended in Dec. 2025 was -2,343.73%.
The historical rank and industry rank for OBI Pharma's FCF Margin % or its related term are showing as below:
ROCO:4174'
s FCF Margin % Range Over the Past 10 Years
Min: -334916.22 Med: -5557.17 Max: -1107.36
Current: -3531.21
During the past 13 years, the highest FCF Margin % of OBI Pharma was -1107.36%. The lowest was -334916.22%. And the median was -5557.17%.
ROCO:4174's FCF Margin % is ranked worse than 87.58% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs ROCO:4174: -3531.21
OBI Pharma FCF Margin % Related Terms
OBI Pharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for OBI Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4174 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, OBI Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OBI Pharma FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OBI Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where OBI Pharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OBI Pharma (ROCO:4174) has a FCF Margin % of -2,343.73% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on OBI Pharma and its competitors. According to the industry distribution chart, OBI Pharma ranks #832 out of 950 companies in the Biotechnology industry, placing it in the top 87.6%.
Is OBI Pharma's FCF Margin % too high?
OBI Pharma's current FCF Margin % is -2,343.73%. Based on the distribution chart, OBI Pharma ranks #832 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OBI Pharma has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OBI Pharma's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OBI Pharma ranks #832 out of 950 companies for FCF Margin %. This places OBI Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on OBI Pharma and its competitors. OBI Pharma's current FCF Margin % is -2,343.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OBI Pharma stock overvalued right now?
Based on GuruFocus' analysis, OBI Pharma (ROCO:4174) is currently considered Possible Value Trap. The stock's GF Value™ is NT$138.61, compared to a current price of NT$28.40 — trading 79.5% below its estimated fair value. The current FCF Margin % is -2,343.73%. OBI Pharma's overall GF Score™ is 43/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For OBI Pharma (ROCO:4174), the current FCF Margin % is -2,343.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OBI Pharma (ROCO:4174) Overvalued in 2026?
Based on GuruFocus' analysis, OBI Pharma stock appears to be undervalued.
The current stock price of NT$28.40 is trading 79.5% below its estimated GF Value™ of NT$138.61.
GuruFocus considers OBI Pharma to be Possible Value Trap.
Key valuation signals for ROCO:4174:
FCF Margin %: -2,343.73%
GF Value™: NT$138.61 vs. price of NT$28.40 (79.5% below fair value)
No single metric tells the full story. See the ROCO:4174 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
43GF Score
Get the complete analysis for ROCO:4174
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4174 has been successfully added to your 
